{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["66(15)"],"submitter":["Chen B"],"pubmed_abstract":["<h4>Purpose</h4>Noninfectious uveitis is a sight-threatening autoimmune eye disease lacking effective targeted therapies. Dipyridamole (DIP), a phosphodiesterase (PDE) inhibitor, has demonstrated anti-inflammatory properties in inflammatory diseases. However, its application in uveitis remains unexplored.<h4>Methods</h4>We used single-cell RNA sequencing (scRNA-seq) data from experimental autoimmune uveitis (EAU) mice and uveitis patients to assess the potential association of PDE gene expression with disease development. Subsequently, EAU mice received oral DIP (300 mg/kg/day), starting at different time points (preventative, early-therapeutic, or late-therapeutic), and treatment efficacy was assessed. To explore immune components and signaling changes, we profiled cervical draining lymph"],"journal":["Investigative ophthalmology & visual science"],"pagination":["16"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12697703"],"repository":["biostudies-literature"],"pubmed_title":["Effect of Dipyridamole on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Pathogenicity."],"pmcid":["PMC12697703"],"pubmed_authors":["Lv J","Wen Y","Huang Z","Chen J","Zhang X","Lin H","Chen B","Wu Y","Su W","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"Effect of Dipyridamole on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Pathogenicity.","description":"<h4>Purpose</h4>Noninfectious uveitis is a sight-threatening autoimmune eye disease lacking effective targeted therapies. Dipyridamole (DIP), a phosphodiesterase (PDE) inhibitor, has demonstrated anti-inflammatory properties in inflammatory diseases. However, its application in uveitis remains unexplored.<h4>Methods</h4>We used single-cell RNA sequencing (scRNA-seq) data from experimental autoimmune uveitis (EAU) mice and uveitis patients to assess the potential association of PDE gene expression with disease development. Subsequently, EAU mice received oral DIP (300 mg/kg/day), starting at different time points (preventative, early-therapeutic, or late-therapeutic), and treatment efficacy was assessed. To explore immune components and signaling changes, we profiled cervical draining lymph","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T01:24:03.222Z","creation":"2026-05-24T03:11:45.683Z"},"accession":"S-EPMC12697703","cross_references":{"pubmed":["41334959"],"doi":["10.1167/iovs.66.15.16"]}}